Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3051
Apogee Enterprises
APOG
$743M
| $1.62M | ﹤0.01% |
44,629
+6,826
| +18% | +$258K |
2013 Q2
50 quarters
|
|
3052
Bristow Group
VTOL
$1.19B
| $1.62M | ﹤0.01% |
44,361
-1,927
| -4% | -$72.5K |
2022 Q1
15 quarters
|
|
3053
Porch Group
PRCH
$1.97B
| $1.62M | ﹤0.01% |
177,803
+41,732
| +31% | +$503K |
2022 Q1
15 quarters
|
|
3054
Bilibili
BILI
$5.95B
| $1.62M | ﹤0.01% |
65,998
+5,917
| +10% | +$159K |
2018 Q4
28 quarters
|
|
3055
Solid Power
SLDP
$532M
| $1.62M | ﹤0.01% |
381,605
+166,815
| +78% | +$921K |
2022 Q1
15 quarters
|
|
3056
Northeast Bank
NBN
$1.09B
| $1.61M | ﹤0.01% |
15,536
+3,472
| +29% | +$324K |
2022 Q2
14 quarters
|
|
3057
Dentsply Sirona
XRAY
$1.73B
| $1.61M | ﹤0.01% |
141,188
-107,085
| -43% | -$1.26M |
2013 Q2
50 quarters
|
|
3058
Janus International
JBI
$574M
| $1.61M | ﹤0.01% |
246,575
+30,987
| +14% | +$241K |
2022 Q1
15 quarters
|
|
|
SEZL
3059
Sezzle
SEZL
$3.62B
| $1.61M | ﹤0.01% |
25,353
+2,684
| +12% | +$183K |
2024 Q1
7 quarters
|
|
3060
CALL
Blackrock
BLK
$164B
| $1.61M | ﹤0.01% |
1,500
-600
| -29% | -$656K |
2025 Q2
2 quarters
|
|
3061
CorMedix
CRMD
$560M
| $1.6M | ﹤0.01% |
137,930
+7,399
| +6% | +$81.8K |
2019 Q1
27 quarters
|
|
3062
iShares 5-10 Year Investment Grade Corporate Bond ETF
IGIB
$18.4B
| $1.6M | ﹤0.01% |
29,677
-5,433
| -15% | -$294K |
2020 Q2
22 quarters
|
|
3063
AdaptHealth
AHCO
$747M
| $1.59M | ﹤0.01% |
159,947
+16,451
| +11% | +$157K |
2022 Q1
15 quarters
|
|
|
RAPP
3064
Rapport Therapeutics
RAPP
$1.54B
| $1.59M | ﹤0.01% |
52,480
+25,767
| +96% | +$713K |
2024 Q2
6 quarters
|
|
|
JAMF
3065
DELISTED
Jamf
JAMF
| $1.59M | ﹤0.01% |
122,046
-49,644
| -29% | -$602K |
2022 Q1
15 quarters
|
|
3066
FIGS
FIGS
$2.25B
| $1.59M | ﹤0.01% |
139,525
-12,402
| -8% | -$116K |
2022 Q1
15 quarters
|
|
3067
Amerant Bancorp
AMTB
$1.16B
| $1.58M | ﹤0.01% |
81,103
+15,843
| +24% | +$295K |
2019 Q1
27 quarters
|
|
3068
Covenant Logistics
CVLG
$857M
| $1.58M | ﹤0.01% |
71,732
+65
| +0.1% | +$1.36K |
2016 Q2
38 quarters
|
|
3069
Astrana Health
ASTH
$1.78B
| $1.58M | ﹤0.01% |
63,639
+5,225
| +9% | +$139K |
2018 Q2
30 quarters
|
|
3070
Southside Bancshares
SBSI
$916M
| $1.57M | ﹤0.01% |
51,590
+9,392
| +22% | +$275K |
2016 Q1
39 quarters
|
|
3071
Sixth Street Specialty
TSLX
$1.72B
| $1.57M | ﹤0.01% |
72,066
-16,851
| -19% | -$368K |
2025 Q3
1 quarter
|
|
3072
Gorman-Rupp
GRC
$2.04B
| $1.56M | ﹤0.01% |
32,758
+2,036
| +7% | +$94.8K |
2023 Q1
11 quarters
|
|
|
CBL
3073
CBL Properties
CBL
$1.69B
| $1.56M | ﹤0.01% |
42,192
+6,815
| +19% | +$222K |
2022 Q1
15 quarters
|
|
3074
PUT
BridgeBio Pharma
BBIO
$13.1B
| $1.56M | ﹤0.01% |
20,400
| – | – |
2025 Q3
1 quarter
|
|
|
GBTG
3075
DELISTED
American Express Global Business Travel
GBTG
| $1.56M | ﹤0.01% |
203,854
-163,671
| -45% | -$1.27M |
2023 Q2
10 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.